Merck pauses 2 more trials of backbone HIV drug over red flag, raising doubts about multipronged R&D strategy

Are the foundations of Merck’s broad HIV development program crumbling? Having already paused combination work in response to a red flag, Merck has now temporarily stopped enrollment in phase 3 studies that are testing the backbone of its HIV strategy as a monotherapy.